COMP <GO>
WST vs DXCM // OPERATING MARGIN
West Pharmaceutical Services Inc. (NYSE) VS. DexCom Inc. (NASDAQ) • 15-METRIC TALLY: WST 3
— DXCM 10
▲ OPERATING MARGIN LEADER: DXCM
LAST: $416.67 (+3.23%) • MKT CAP: $29.32B
operating-margins
19.00%
LAST: $79.93 (+1.67%) • MKT CAP: $30.16B
operating-margins
19.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WST VS. DXCM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WST | DXCM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.90% | 60.10% | -24.20 | DXCM | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.90% | 21.60% | -3.70 | DXCM | /roic <GO> |
| EV/EBITDA & P/E Valuation | 34.7x | 25.2x | +9.50 | DXCM | /valuation <GO> |
| Free Cash Flow Yield | 1.60% | 3.57% | -1.97 | DXCM | /fcf-yield <GO> |
| Operating Margin ACTIVE | 19.00% | 19.60% | -0.60 | DXCM | /operating-margins <GO> |
| Net Profit Margin | 16.10% | 17.90% | -1.80 | DXCM | /net-margins <GO> |
| Revenue Growth (YoY) | 6.30% | 15.60% | -9.30 | DXCM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.21% | 0.00% | +0.21 | WST | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 19.06 | 7.14 | +11.92 | WST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 77.0 | 41.8 | +35.20 | WST | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.10 | -0.02 | DXCM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 55.2x | 30.3x | +24.90 | DXCM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $29.32B | $30.16B | -$839.0M | DXCM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WST REV | DXCM REV | WST GROSS % | DXCM GROSS % | WST FCF | DXCM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.07B | $4.66B | 35.9% | 60.1% | $468.9M | $1.08B |
| FY 2024 | $2.89B | $4.03B | 34.5% | 60.5% | $276.4M | $630.7M |
| FY 2023 | $2.95B | $3.62B | — | — | $643.8M | $585.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WST // BETA 1.08
DXCM // BETA 1.10